Chronic hepatitis C virus infection and its treatment impact patients' health-related quality of life.
Dr Vera-Llonch from Massachussetts, USA reported on treatment impact and predictors of health-related quality of life among treatment-naïve patients with genotype 1 chronic hepatitis C virus infection who received 12-week telaprevir with 24 or 48 weeks peginterferon alpha-2a/ribavirin, or 48 weeks of PR in the ADVANCE study.
The team reported that the EQ-5D-3L questionnaire was completed at baseline and weeks 4, 12, 24, 36, 48 and 72.
Patients indicated their health state on five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Data from 722 patients were included.
|Sustained virological response was associated with 4% improved EQ-5D index|
|Alimentary Pharmacology & Therapeutics|
The researchers found that the mean EQ-5D index decreased during the first 12 weeks, and returned to baseline by week 72 across treatments.
The team observed that sustained virological response at week 72 was associated with improved EQ-5D index, a 4% difference, within the published range of minimal clinically important difference.
Dr Vera's team commented, "Post hoc analyses of data from ADVANCE suggested that health-related quality of life worsened during the first 12 weeks of therapy, and returned to baseline by week 72 across treatments."
"Improvements were observed early following completion of a 24-week treatment."
"Telaprevir combination therapy was associated with slightly higher reductions in health-related quality of life during the first 12 weeks."
"Sustained virological response was a statistically significant and meaningful predictor of health-related quality of life at week 72."